Literature DB >> 18575457

Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse.

Adám Dénes1, Szilamér Ferenczi, József Halász, Zsuzsanna Környei, Krisztina J Kovács.   

Abstract

CX3CR1 (fractalkine receptor) is important for sustaining normal microglial activity in the brain. Lack of CX3CR1 reportedly results in neurotoxic microglial phenotype in disease models. The objective of this study was to test the hypothesis that the absence of CX3CR1 worsens the outcome in cerebral ischemia. We observed significantly smaller (56%) infarcts and blood-brain barrier damage in CX3CR1-deficient (CX3CR1-/-) animals compared with CX3CR1+/- and wild-type mice after transient occlusion of the middle cerebral artery (MCAo). Functional recovery of CX3CR1-/- animals was enhanced, while less number of apoptotic cells and infiltrating leukocytes were found in the ipsilateral hemisphere. Expression of IL-1beta mRNA, protein, and interleukin (IL)-1Ra and tumor necrosis factor (TNF)-alpha mRNAs was lower in CX3CR1-/- mice, whereas no difference was observed in the number of IL-1beta-expressing microglia or plasma IL-1beta concentration. We observed early IL-1beta expression in astrocytes in vivo after MCAo and after oxygen-glucose deprivation in vitro, which might contribute to the ischemic damage. Our findings indicate that lack of CX3CR1 does not result in microglial neurotoxicity after MCAo, but rather significantly reduces ischemic damage and inflammation. Reduced IL-1beta and TNFalpha expression as well as decreased leukocyte infiltration might be involved in the development of smaller infarcts in CX3CR1-/- animals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575457     DOI: 10.1038/jcbfm.2008.64

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  133 in total

1.  Regulation of tau pathology by the microglial fractalkine receptor.

Authors:  Kiran Bhaskar; Megan Konerth; Olga N Kokiko-Cochran; Astrid Cardona; Richard M Ransohoff; Bruce T Lamb
Journal:  Neuron       Date:  2010-10-06       Impact factor: 17.173

Review 2.  The immunology of neurodegeneration.

Authors:  Eva Czirr; Tony Wyss-Coray
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 3.  Microglial activation in stroke: therapeutic targets.

Authors:  Midori A Yenari; Tiina M Kauppinen; Raymond A Swanson
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

4.  CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.

Authors:  Sungho Lee; Nicholas H Varvel; Megan E Konerth; Guixiang Xu; Astrid E Cardona; Richard M Ransohoff; Bruce T Lamb
Journal:  Am J Pathol       Date:  2010-09-23       Impact factor: 4.307

5.  Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration.

Authors:  Tomasz Jaworski; Benoit Lechat; David Demedts; Lies Gielis; Herman Devijver; Peter Borghgraef; Hans Duimel; Fons Verheyen; Sebastian Kügler; Fred Van Leuven
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

6.  Fractalkine attenuates excito-neurotoxicity via microglial clearance of damaged neurons and antioxidant enzyme heme oxygenase-1 expression.

Authors:  Mariko Noda; Yukiko Doi; Jianfeng Liang; Jun Kawanokuchi; Yoshifumi Sonobe; Hideyuki Takeuchi; Tetsuya Mizuno; Akio Suzumura
Journal:  J Biol Chem       Date:  2010-11-11       Impact factor: 5.157

Review 7.  Microglial interactions with the neurovascular system in physiology and pathology.

Authors:  Xiaoliang Zhao; Ukpong B Eyo; Madhuvika Murugan; Long-Jun Wu
Journal:  Dev Neurobiol       Date:  2018-02-01       Impact factor: 3.964

8.  Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain.

Authors:  Nicole Maphis; Guixiang Xu; Olga N Kokiko-Cochran; Shanya Jiang; Astrid Cardona; Richard M Ransohoff; Bruce T Lamb; Kiran Bhaskar
Journal:  Brain       Date:  2015-03-31       Impact factor: 13.501

9.  Future Perspectives for Brain Pharmacotherapies: Implications of Drug Transport Processes at the Blood-brain Barrier.

Authors:  Dirk M Hermann
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

10.  Genetic neutrophil deficiency ameliorates cerebral ischemia-reperfusion injury.

Authors:  Ryan A Frieler; Yutein Chung; Carolyn G Ahlers; George Gheordunescu; Jianrui Song; Thomas M Vigil; Yatrik M Shah; Richard M Mortensen
Journal:  Exp Neurol       Date:  2017-08-31       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.